BioSpace News Archive

Pharm Country

Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on March 6, 2024

Intelligent Bio Solutions Inc. today announced that it will present at the Emerging Growth Conference on March 6, 2024.

March 1, 2024
·
2 min read
Deals

NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share

NRx Pharmaceuticals, Inc. today announced that it entered into a definitive purchase agreement subject to standard closing conditions with an accredited investor to purchase approximately 2.7 million shares of unregistered common stock at $0.38 per share.

March 1, 2024
·
5 min read
Biotech Bay

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories - March 1, 2024

Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.

March 1, 2024
·
8 min read
Business

Cutera to Announce Fourth Quarter and Full-Year 2023 Results on March 21, 2024

Cutera, Inc. today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Thursday, March 21, 2024.

March 1, 2024
·
4 min read
Biotech Beach

Evolus Announces Results from European Head-to-Head Filler Trial

Evolus, Inc. today announced that it will provide the data presented at IMCAS during its upcoming Earnings conference call on March 7th at 4:30 p.m. ET.

March 1, 2024
·
4 min read
Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

Mallinckrodt plc, a global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Mallinckrodt’s supplemental New Drug Application (sNDA) for the Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector.

March 1, 2024
·
10 min read
NMPA Approves the NDA for CARsgen’s BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited announces that today the National Medical Products Administration (“NMPA”) of China has approved the New Drug Application (“NDA”) for zevorcabtagene autoleucel.

March 1, 2024
·
6 min read
Inoviv Launches NeuroKey-3™, A Quantitative Multiplexed IP-MS Assay to Measure Key Low-Level Markers in Neurodegeneration

Biomarker pioneer, Inoviv, announces the launch of its proprietary NeuroKey-3™ assay, an end-to-end service offering to measure key low-level markers in neurodegeneration in human plasma.

March 1, 2024
·
2 min read
Pharm Country

Mitsubishi Tanabe Pharma America to Showcase Presentations on ALS Research at 2024 MDA Clinical & Scientific Conference

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held in Orlando, Fla., March 3-6.

March 1, 2024
·
7 min read
Biotech Bay

BioMarin Scheduled to Participate in March Investor Conferences

BioMarin Pharmaceutical Inc. today announced management is scheduled to participate in four upcoming investor conferences in March.

March 1, 2024
·
2 min read